Latest news and press releases about Radiopharm Theranostics Limited (RADX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Radiopharm Theranostics Limited, an Australian company established in Carlton in 2021, specializes in the research and development of cutting-edge radiopharmaceutical treatments. Their mission is to address critical gaps in healthcare by creating products for both diagnostic imaging and therapeutic intervention across a spectrum of challenging medical conditions.
Price
| Price | $1.67 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | AU |
Valuation Ratios
| Price / Book | 2.21 |
| EV / EBITDA | -1.01 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -218.50% |
| Return on Invested Capital | -161.91% |
| Return on Assets | -89.70% |
| Gross Margin | -77.67% |
| Operating Margin | -2468.62% |
| Net Margin | -1992.46% |
Related companies: ADXN · BCLI · CDIO · CYCN · IBO · KTTA · MTNB
Explore sector: Healthcare · Biotechnology
More sections of RADX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks